Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Depatuxizumab mafodotin
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric/humanized hybrid (mouse/human) |
Target | EGFR |
Clinical data | |
Other names | ABT-414 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6624H10228N1728O2052S42 |
Molar mass | 148251.25 g·mol−1 |
Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.
This drug was developed by AbbVie. In May 2019 AbbVie stopped enrolment in all studies of Depatux-M after late-stage failure in newly diagnosed glioblastoma.
In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme. It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors. Phase I results were presented at ASCO in 2016.